Elicio Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 121.6K | $1.30M | 0.00% | Added+332.7% | 2026-03-31 |
| StateStreet | passive | 50.6K | $541.13K | 0.00% | Added+9.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-11 | -0.46 | -0.65 | -39.78% |
| 2026-03-12 | -0.44 | -0.49 | -10.11% |
| 2025-11-13 | -0.48 | -0.60 | -25.00% |
| 2025-08-07 | -0.68 | -0.66 | +3.65% |
| 2025-05-13 | -0.83 | -0.87 | -4.82% |
| 2025-03-31 | -0.87 | -1.02 | -16.57% |
| 2024-11-13 | -0.73 | -1.39 | -90.41% |
| 2024-08-13 | -0.96 | -0.64 | +33.33% |
| 2024-05-15 | -1.09 | -1.15 | -5.50% |
| 2024-03-29 | -1.03 | -3.78 | -266.99% |
| 2023-11-09 | -0.80 | -1.27 | -58.75% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ELTX | +6.42% | -8.48% | +43.72% | +58.23% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.45% | -3.84% | +47.16% | +45.54% |